Table 2.

Subject Characteristics Prior to Treatment

	Demographics		McGill
All Subjects	Age	% male	I-a	I-b	I-a+b	II	III
Celliant™	57.7 ± 11.8	70%	1.2 ± 0.8	0.6 ± 0.7	1.9 ± 1.5	4.7 ± 2.4	2.6 ± 1.0
Control	61.6 ± 11.8	68%	1.3 ± 0.7	1.1 ± 1.0	2.4 ± 1.6	5.4 ± 2.8	3.1 ± 1.1
DPN group
Celliant™	63.0 ± 7.7	85%	1.2 ± 0.9	0.6 ± 0.7	1.9 ± 1.5	5.1 ± 2.6	2.7 ± 1.1
Control	63.9 ± 11.0	77%	1.4 ± 0.7	1.2 ± 1.1	2.5 ± 1.7	5.2 ± 2.9	2.9 ± 0.9
Non-DPN group
Celliant™	52.7 ± 13.1	57%	1.2 ± 0.8	0.6 ± 0.8	1.9 ± 1.5	4.4 ± 2.3	2.4 ± 0.9
Control	59.5 ± 12.3	60%	1.3 ± 0.8	1.1 ± 1.0	2.3 ± 1.6	5.6 ± 2.8	3.3 ± 1.2
	Brief Pain Inventory
All Subjects	Pain Severity		Pain Interference	VAS		SF-36: Bodily Pain
Celliant™	4.2 ± 2.4		5.8 ± 2.4	37.8 ± 8.1		4.2 ± 2.4
Control	5.5 ± 2.6		6.4 ± 1.8	34.6 ± 7.8		5.5 ± 2.6
DPN group
Celliant™	4.9 ± 2.0		4.7 ± 2.5	5.9 ± 2.4		34.2 ± 7.4
Control	5.1 ± 2.3		5.5 ± 2.9	6.1 ± 1.9		36.1 ± 7.5
Non-DPN group
Celliant™	3.9 ± 1.9*		3.8 ± 2.3*	5.8 ± 2.5		40.8 ± 7.7
Control	5.3 ± 1.6*		5.6 ± 2.3*	6.6 ± 1.8		33.3 ± 8.1

*denotes significant (p < 0.05) differences between Celliant™ and Control subjects.